| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8442147 | European Journal of Cancer | 2015 | 10 Pages |
Abstract
Bevacizumab, whether or not in combination with lomustine, did not negatively affect HRQoL in patients treated for recurrent glioblastoma in this randomised study.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Linda Dirven, Martin J. van den Bent, Andrew Bottomley, Nelly van der Meer, Bronno van der Holt, Maaike J. Vos, Annemiek M.E. Walenkamp, Laurens V. Beerepoot, Monique C.J. Hanse, Jaap C. Reijneveld, Aja Otten, Filip Y.F.L. de Vos, Marion Smits,